References
- 1. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004; 291:2581-2590.
- 2. WHO, Fact Sheet – Mental Health 2019, Accessed 04.03.2019 at: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/data-and-resources/fact-sheet-mental-health-2019.
- 3. Hinkov H, Dimitrov P, Zarkov Z et al. National Representative Epidemiological Study Of Common Mental Disorders In Bulgaria Epibul 2, 2016-2017: Tool, Methodology, Process Evaluation. Soc Med. 2017; 1: 21-23.
- 4. Katz MM, Koslow SH, Berman N et al. A multi-vantaged approach to measurement of behavioral and affect states for clinical and psychobiological research. Psychol Rep. 1984; 55:619-671.
- 5. Katz MM, Maas JW. Psychopharmacology and the etiology of psychopathological states: are we looking in the right way? Neuropsychopharmacology. 1994; 10:139-144.
- 6. Mimura M. Comorbidity of Depression and Other Diseases. JMAJ 2001; 44(5): 225-229.
- 7. Kendler KS, Neale M, Kessler R et al. A twin study of recent life events and difficulties. Arch Gen Psychiatry. 1993; 50:789-796.
- 8. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in women. Am J Psychiatry. 2002; 159:1133-1145.
- 9. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry. 2001; 158:582-156.
- 10. Goodwin GM. Depression and associated physical diseases and symptoms. Dialogues Clin Neurosci. 2006; 8(2):259-265.
- 11. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965; 122(5):509-22.
- 12. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry. 1965; 13(6):483-94.
- 13. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000; 61 S6:4-6.
- 14. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000; 61 S6:7-11.
- 15. Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occurring during Rauwolfia therapy. J Am Med Assoc. 1955; 29; 159(9):836-9.
- 16. Shore PA, Silver SL, Brodie BB.Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science. 1955; 122(3163):284-5.
- 17. Shore PA, Pletscher A, Tomich EG et al. Role of brain serotonin in reserpine action. Ann N Y Acad Sci. 1957; 66(3):609-15; discussion, 615-7.
- 18. Weiner N, Cloutier G, Bjur R, Pfeffer RI. Modification of norepinephrine synthesis in intact tissue by drugs and during short-term adrenergic nerve stimulation. Pharmacol Rev. 1972; 24(2): 203-221.
- 19. Mann JJ. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol. 1983; 3:363-366.
- 20. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment respond to increased fluoxetine dose. J. Clin Psychiatry. 1995; 56:52-55.
- 21. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord. 2001; 64:99-106.
- 22. Drevets WC, Price JL, Simpson JR Jr et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997; 386:824-827.
- 23. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013; 14:609-625.
- 24. Rajkowska G, Miguel-Hidalgo JJ, Wei J et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999; 45:1085-1098.
- 25. Kang HJ, Kim JM, Lee JY et al. BDNF promoter methylation and suicidal behavior in depressive patients. J Affect Disord. 2013; 151:679-685.
- 26. Duric V, Banasr M, Stockmeier CA et al. Altered expression of synapse and glutamate related genes in postmortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013; 16:69-82.
- 27. 2Morales-Medina JC, Juarez I, Venancio-Garcia E et al. Impaired structural hippocampal plasticity is associated with emotional and memory deficits in the olfactory bulbectomized rat. Neuroscience. 2013; 236:233-243.
- 28. Willner P, Scheel-Krüger J. The neurobiology of depression and antidepressant action. Neuroscience and Biobehavioral Reviews 2013; 37: 2331-2371.
- 29. Bremner JD, Randall P, Scott TM et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995; 152: 973-981.
- 30. Lee T, Jarome T, Li SJ, Kim JJ, Helmstetter FJ. Chronic stress selectively reduces hippocampal volume in rats: a longitudinal magnetic resonance imaging study. Neuroreport. 2009; 20: 1554-1558.
- 31. Conrad CD, LeDoux JE, Magarinos AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci. 1999; 113: 902-913.
- 32. Schoenfeld TJ, Gould E. Stress, stress hormones, and adult neurogenesis. Exp Neurol. 2012; 233:12-21.
- 33. Grønli J, Bramham C, Murison R et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in thedentate gyrus but not in the hippocampus proper. Pharm Bio Behav. 2006; 85(4):842-9.
- 34. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 1997; 54(7):597-606.
- 35. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry. 2006; 59(12):1116-1127.
- 36. Björkholm C, Monteggia LM. BDNF – a key transducer of antidepressant effects. Neuropharmacology. 2016; 102:72–79. doi:10.1016/j.neuropharm.2015.10.034
- 37. Levinson, D. The genetics of depression: a review. Biological Psychiatry. 2006; 60 (2): 84-92.
- 38. Maurice, DH, Ke, H, Ahmad, F et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 2014; 13, 290-314.
- 39. Rose, GM, Hopper, A, De Vivo, M, Tehim, A. Phosphodiesterase inhibitors for cognitive enhancement. Curr. Pharm. Des. 2005; 11:3329-3334.
- 40. García-Osta, A, Cuadrado-Tejedor, M, Garcia-Barroso, C et al. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem. Neurosci. 2012; 3:832-844.
- 41. Pearse, DD, Hughes, ZA. PDE4B as a microglia target to reduce neuroinflammation. Glia. 2016; 64:1698-1709.
- 42. Zou, ZQ, Chen, JJ, Feng, HF et al. Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP/PKA/CREB signaling pathway and NF-kappaB Inhibition. J. Pharmacol. Exp. Ther. 2017; 362, 67-77.
- 43. Yu, H, Zou, Z, Zhang, X et al. Inhibition of phosphodiesterase 4 by FCPR03 alleviates lipopolysaccharide-induced depressive-like behaviors in mice: involvement of p38 and JNK signaling pathways. Int. J. Mol. Sci. 2018; 19: E513.
- 44. Kuo DC, Tran M, Shah AA, et al. Depression and the suicidal patient. Emerg Med Clin North Am 2015; 33:765-78.
- 45. Riede, HL. Fourth-generation fluoroquinolones in tuberculosis. Lancet. 2009; 373 (9670): 1148-1149.
- 46. Fox H, Gibas T. Synthetic tuberculostats. V. Alkylidene derivatives of isonicotinyhydrazineJ. Org. Chem. 1953; 18(8): 983-989
- 47. Loomer, HP, Saunders, JC, Kline, NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatric Research Reports. 1957; 8:129-141.
- 48. Chockalingam R, Gott BM, Conway CR. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look? Handbook of Experimental Pharmacology. 2019;250:37-48.
- 49. Walker FG. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology, 2013; 67: 304-317.
- 50. Lu Y, Mak KK, Van Bever HP, et al Prevalence of anxiety and depressive symptoms in adolescents with asthma: a meta-analysis and meta-regression. Pediatr Allergy Immunol. 2012; 23:707-715.
- 51. Lim VZ, Ho RC, Tee SI, et al. Anxiety and depression in patients with atopic dermatitis in a Southeast Asian tertiary dermatological center. Ann Acad Med Singapore 2016.
- 52. Zhang MW, Ho RC, Cheung MW, et al. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2011; 33:217-23.
- 53. Mak A, Tang CS, Chan MF, et al. Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus. Clin Rheumatol 2011.
- 54. Ho RC, Fu EH, Chua AN, et al. Clinical and psychosocial factors associated with depression and anxiety in Singaporean patients with rheumatoid arthritis. Int J Rheum Dis 2011; 14:37-47.
- 55. Mak KK, Kong WY, Mak A, et al. Polymorphisms of the serotonin transporter gene and post-stroke depression: a meta-analysis. J Neurol Neurosurg Psychiatry 2013.
- 56. Liddell, Henry and Robert Scott (1980). A Greek-English Lexicon (Abridged Edition). United Kingdom: Oxford University Press. ISBN 0-19-910207-4.
- 57. Kessler, RC, Soukup, J, Davis, RB et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am. J. Psychiatry. 2001; 158:289-294.
- 58. Harvey, AL, Young, LC, Viljoen, AM, Gericke, NP. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology. 2011; 137(3):1124-1129.
- 59. Hanks, GR. (ed.). Narcissus and daffodil: The genus Narcissus. CRC Press, Boca Raton, FL, 2003.
- 60. Heinrich, M, Barnes, J, Gibbons, S, Williamson, E. Fundamentals of Pharmacognosy and Phytotherapy. Churchill Livingstone, London, 2004.
- 61. Kumar, V. Potential medicinal plants for CNS disorders: an overview. Phytother. Res. 2006; 20(12):1023-1035.
- 62. Spinella, M. The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior (Paperback). MIT Press, Cambridge, 2001.
- 63. Rahimi, R, Nikfar, S, Abdollahi, M. Efficacy and tolerability of Hypericum perforatumin major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33:118-127.
- 64. Buket B, Ahmet E, Gulen K et al. Somer. Alkaloid Profiling of Galan-thus woronowii Losinsk. by GC-MS and evaluation of its biological activity. Marmara Pharmaceutical Journal. 2017; 21 (4):915-920.
- 65. Berkov, S, Osorio E, Viladomat F, Bastida J. Chapter Two – Chemodiversity, chemotaxonomy and chemoecology of Amaryllidaceae alkaloids. The Alkaloids: Chemistry and Biology. 2020; 83: 113-185.
- 66. Artyushenko, ZT. Amaryllidaceae of USSR, morphology, taxonomy and use. Nauka, Leningrad, Russia, 1970.
- 67. Khamidkhodzhaev, SA. Biology, resources and introduction of medicinal plants of Ungernia Bunge and Ficus L. in Middle Asia. Main Botanical Garden, Moscow, Russia, Dr. Sci. Diss. Abstr, 1984.
- 68. Pigni, NB, Berkov, S, Elamrani, A, et al. Two New Alkaloids from Narcissus serotinus L.. Molecules, 2010; 15: 7083-7089.
- 69. Birks, J Birks, Jacqueline S. Cholinesterase inhibitors for Alzheimer’s disease. The Cochrane Database of Systematic Reviews. 2006; 1: CD005593.
- 70. Bodendorf, K, Krieger, W. Alkaloids of Mesembryanthemum tortuosum. Arch. Pharm. 1957; 290:441.
- 71. Smith, MT, Crouch, NR, Gericke, N, Hirst, M. Psychoactive Constituents of the Genus Sceletium N.E.Br. and other Mesembryanthemaceae: A Review. Journal of Ethnopharmacology. 1996; 50(3):119-130.
- 72. Gericke, N, Van Wyk, B. In African Natural Health CC(Ed.), Pharmaceutical compositions containing mesembrine, 2001.
- 73. Harvey, A. In Gericke N. (Ed.), Personal communication to Nigel Gericke, 2008.
- 74. Napoletano M, Norcini G, Pellacini F et al. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives. Bioorg Med Chem Lett. 2001;11(1):33-7.
- 75. Houslay, M, Schafer, P, Zhang, K. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today. 2005; 15:11503.
- 76. Fujimaki, K, Morinobu, S, Duman, R. Administration of a cAMP Phosphodiesterase 4 Inhibitor Enhances Antidepressant-Induction of BDNF mRNA in Rat Hippocampus. Neuropsychopharmacol, 2000; 22: 42-51.